All In MedTech

FDA Clearance Tracker · P140015-S021

t:slim G4 Insulin Pump with Dexcom G4 Platinum CGM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 21, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 21, 2017

Approved

Time to decision

262 days

Received Apr 3, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P140015-S021
Device name
t:slim G4 Insulin Pump with Dexcom G4 Platinum CGM
Applicant location
San Diego, CA
Received
Apr 3, 2017
Decided
Dec 21, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P140015

Device type

Device class
Class III

Every decision under product code OYC

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site change of the t:Slim G4 Insulin Pump, which is used with the Dexcom G4 Platinum CGM, from their old facility at 11045 Roselle St, San Diego, California to their new facility at 10151 Barnes Canyon Rd, San Diego, California.

Source documents

Other decisions for Tandem Diabetes Care, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.